Management of neonatal abstinence syndrome from opioids

Most infants at risk for neonatal abstinence syndrome have opioid plus another drug exposure; polypharmacy is the rule rather than the exception. Scales for evaluation of neonatal abstinence syndrome are primarily based for opioid withdrawal. A standard protocol to treat neonatal abstinence syndrome...

Full description

Saved in:
Bibliographic Details
Published inClinics in perinatology Vol. 40; no. 3; p. 509
Main Authors Grim, Kendra, Harrison, Tracy E, Wilder, Robert T
Format Journal Article
LanguageEnglish
Published United States 01.09.2013
Subjects
Analgesics, Opioid - adverse effects
Analgesics, Opioid - therapeutic use
Buprenorphine - therapeutic use
Feeding Methods
Humans
Infant Care - methods
Infant, Newborn
Methadone - therapeutic use
Morphine - therapeutic use
Neonatal Abstinence Syndrome - therapy
Opiate Substitution Treatment - methods
Pacifiers
Treatment Outcome
Neonatal
Methadone
Buprenorphine
Withdrawal
Abstinence
Opioids
Online AccessGet more information

Cover

More Information
Summary:Most infants at risk for neonatal abstinence syndrome have opioid plus another drug exposure; polypharmacy is the rule rather than the exception. Scales for evaluation of neonatal abstinence syndrome are primarily based for opioid withdrawal. A standard protocol to treat neonatal abstinence syndrome has not been developed. Institute nonpharmacologic strategies for all neonates at risk. The American Academy of Pediatrics recommends mechanism-directed therapy (treat opioid withdrawal with an opioid) as the first-line therapy. Second-line medications are currently under evaluation.
ISSN:1557-9840
DOI:10.1016/j.clp.2013.05.004